You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing Novel Antibiotics Against Yersinia pestis

    SBC: NOVOBIOTIC PHARMACEUTICALS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop broad-spectrum antibiotics against Yersinia pestis and other important human pathogens. The potential use of engineered, multi-drug-resistant strains as agents of bioterrorism necessitates the development of new anti-Y. pestis therapies. This is a challenging goal, since the last novel class of broad-spectrum antib ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Enhancing Situational Awareness to Counter Swarming and Other Nonlinear, Dispersed Tactics Against Naval Surface Forces

    SBC: Systems & Technology Research LLC            Topic: N122117

    The Advanced Electronic Development Program (AEDP) will develop prototypes of photonic and digital components. Under AEDP, electronic equipment will be developed and prototyped, with components integrated for a capability demonstration. This work will be performed under the Phase II SBIR program.

    SBIR Phase II 2018 Department of DefenseDefense Advanced Research Projects Agency
  3. Modeling the Impact of Technology Transition on Ship Operational Capabilities

    SBC: BEACON INTERACTIVE SYSTEMS LLC            Topic: N05053

    During Phase I, we experimented with several transition approaches and ran into three hurdles: 1) No matter how good the method for transitioning technology, if the development process has not been well-managed, there will be no technology to transition; 2) Transition does not happen without an incredible amount of expertise and data; 3) Good technology does not matter if no one is aware of its e ...

    SBIR Phase II 2006 Department of DefenseNavy
  4. TDP-43 aggregation inhibitors for the treatment of ALS

    SBC: Aquinnah Pharmaceuticals Inc.            Topic: 105

    Abstract Amyotrophic Lateral SclerosisALSis a universally fatal neurodegenerative disease that afflicts overout of everyindividualsProtein aggregation has been implicated as a primary driving force in ALS and multiple other neurodegenerative illnessesTDPis the principle component of the protein aggregates in ALSand TDPalso stands out as the only genetically defined ALS mutant gene that is also the ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Discovery of B. pseudomallei therapeutics for Biodefense

    SBC: MICROBIOTIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Burkholderia pseudomallei is a bioterrorist threat. With the best current therapies, lethality is typically as high as 40%. The overall goal of this proposal is the development of new drugs against this organism. In Phase I, the high sequence similarity between 8. pseudomallei and its less virulent relative Pseudomonas aeruginosa was exploited to build innovati ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer

    SBC: PRIVO TECHNOLOGIES, LLC            Topic: NCI

    Preceding Award: NCI Award 1R44CA192875-02 Project Summary: According to the Oral Cancer Foundation, about 50,000 people in the US will be newly diagnosed with oral cancer (OC) in 2017, causing 9,700 deaths[1]. OC is a severely neglected orphan disease with a lack of significant treatment advances in 4 decades[1]. Historically, OC has been present in heavy smokers and drinkers. However, more recen ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Automated Assistance with Metadata Generation (A2MG) Tools for PBA/IPB

    SBC: CHILIAD PUBLISHING, INC.            Topic: AF05098

    Chiliad's Phase II effort will implement and test enhancements and extensions of automated metadata generation capabilities designed in Phase I, and the tight integration of those capabilities with other software systems and applications. Some of the results of Chiliad’s SBIR funded efforts have already been deployed in operational production systems across the FBI, within new releases of the Bu ...

    SBIR Phase II 2006 Department of DefenseAir Force
  8. Vector Identification and Gene Delivery Approach in Pigs

    SBC: GWATHMEY, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Heart failure (HF) represents an enormous clinical problem demanding effective therapeutic approaches. Despite advances in traditional approaches to its treatment, including pharmacological management, myocardial revascularization, mechanical assist devices, and transplantation, heart failure remains a leading cause of death worldwide. Therefore, a novel therap ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Puerarin to Reduce Alcohol Drinking

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This application is a resubmission in response to AA-04-002 from the National Institute on Alcohol Abuse and Alcoholism to continue our STTR (Phase I and II) study on the development of NPI-031G (Puerarin), an Isoflavone-C-glycoside isolated from Puerira lobota (Kudzu), as a botanical anti-craving agent for the treatment of alcohol drinking problems. In STTR ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  10. SBIR TOPIC 096:Novel Biodegradable Stents for Neonatal Aortic Coarctation

    SBC: Lyra Therapeutics, Inc.            Topic: NHLBI

    Aortic coarctation is a common congenital heart condition that is usually recognized during the neonatal period early after birth The usual treatment is open surgery Non surgical catheter based stent therapy is not available to treat neonatal aortic coarctation because children outgrow commercially available metallic stents Absorbable stents might revolutionize the treatment of aortic coarctation ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government